Cardiovascular Complications of Novel Multiple Myeloma Treatments.

Case presentation: A 75-year-old woman was referred to cardiology for optimization of cardiovascular risk factors before starting a new cancer treatment. She was diagnosed with IgG-κ multiple myeloma (MM) 2 years previously that progressed after her previous treatments. Her medical history also included type 2 diabetes mellitus, hypertension, and a remote history of deep vein thrombosis treated with a “blood thinner” for 6 months. Her hematologist has determined that a combination of carfilzomib, lenalidomide, and dexamethasone is the best treatment option for this patient but is concerned about the risk of cardiovascular complications from the new treatment and wants the patient to undergo evaluation by a cardiologist.